Groupe hospitalier Bichat Claude Bernard — Paris

Public research footprint of Groupe hospitalier Bichat Claude Bernard, compiled from the ClinicalTrials.gov public registry.

Registered studies

Active

Recruiting now

Completed

Stopped or withdrawn

Most-studied conditions

Melanoma · Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm… · Patients With Atrial Fibrillation at Risk for Thrombus Formation… · Idiopathic Pulmonary Fibrosis

Recently updated registry entries

NCT07048795 — Impact of the Mylife CamAPS FX System With the DEXCOM G6 Sensor on T1D Patients in France (Recruiting)
NCT06005428 — Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular… (Terminated)
NCT01556035 — Lenalidomide in Relapsed or Refractory Primary-cutaneous Large B-cell Lymphoma Leg-type… (Completed)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at Groupe hospitalier Bichat Claude Bernard?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 05, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.